2024
Glioblastom – aktuelle Therapiekonzepte
Rieger D, Renovanz M, Kurz S, Bombach P, Paulsen F, Roder C, Tatagiba M, Niyazi M, Tabatabai G. Glioblastom – aktuelle Therapiekonzepte. Die Onkologie 2024, 30: 145-156. DOI: 10.1007/s00761-024-01473-7.Peer-Reviewed Original ResearchClinical trialsWorld Health Organization classificationCombination of radiotherapyFirst-line therapyDiagnosis of glioblastomaPatterns of disease progressionTherapeutic clinical trialsTumor Treating FieldsCurrent treatment conceptsCentral nervous systemNeuro-oncology careTemozolomide chemotherapyFirst-linePostoperative therapyPrimary neoplasmsOrganization classificationUnfavorable prognosisTumor progressionClinical statusDisease progressionTreatment conceptTreatment recommendationsBiomarker-basedNervous systemGlioblastomaEfficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review
Grant M, Stockhammer P, Austin M, Nemeth Z, Petrylak D. Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review. Bladder Cancer 2024, 10: 9-23. PMID: 38993528, PMCID: PMC11181835, DOI: 10.3233/blc-230070.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaAntibody-drug conjugatesClinical trialsUrothelial carcinomaCombination regimensDrug conjugatesSystematic reviewAnti-PD-1 agentsProspective therapeutic clinical trialsCochrane Central TrialsClinical trial cohortObjective response rateTherapeutic clinical trialsMeta-Analyses (PRISMA) statementNon-duplicated articlesPreferred Reporting ItemsComprehensive systematic reviewPotent cytotoxic payloadTrial cohortEnfortumab vedotinOvid EmbaseSacituzumab govitecanADC targetImpressive efficacyOvid MEDLINE
2022
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Bakouny Z, Labaki C, Bhalla S, Schmidt A, Steinharter J, Cocco J, Tremblay D, Awad M, Kessler A, Haddad R, Evans M, Busser F, Wotman M, Curran C, Zimmerman B, Bouchard G, Jun T, Nuzzo P, Qin Q, Hirsch L, Feld J, Kelleher K, Seidman D, Huang H, Anderson-Keightly H, Zarif T, Alaiwi S, Champagne C, Rosenbloom T, Stewart P, Johnson B, Trinh Q, Tolaney S, Galsky M, Choueiri T, Doroshow D. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Annals Of Oncology 2022, 33: 836-844. PMID: 35715285, PMCID: PMC9197329, DOI: 10.1016/j.annonc.2022.04.071.Peer-Reviewed Original ResearchConceptsTherapeutic clinical trialsClinical trialsPatient accrualCancer Outcomes StudyNon-white patientsOncological clinical trialsLarge academic centerEarly pandemic periodClinical trial activityCOVID-19Clinical trial conductMulticenter studyNew patientsOncological trialsDirect infectionOutcome studiesPatientsAcademic centersTrial activationTrial conductNormal levelsCohortProgressive recoveryTrialsRacial disparities
2021
Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.
Xiang J, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Perry L, Connery D, Rose M, Chao H. Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience. Journal Of Clinical Oncology 2021, 39: 79-79. DOI: 10.1200/jco.2020.39.28_suppl.79.Peer-Reviewed Original ResearchLung cancer patientsCancer CenterClinical research recruitmentStudy enrollmentCancer patientsClinical trialsPotential eligibilityEligibility criteriaNew lung cancer patientsResearch enrollmentPotential study patientsCancer Center experienceTherapeutic clinical trialsNumber of patientsDiagnosis of cancerResearch recruitmentEligible patientsMalignancy workupPrimary oncologistStudy patientsChart reviewClinic visitsGenitourinary cancersPatient demographicsCenter experience
2020
Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
Weiss SA, Zito C, Tran T, Heishima K, Neumeister V, McGuire J, Adeniran A, Kluger H, Jilaveanu LB. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal Of Neuro-Oncology 2020, 152: 15-25. PMID: 32974852, PMCID: PMC7910371, DOI: 10.1007/s11060-020-03619-0.Peer-Reviewed Original ResearchConceptsT-cell contentMelanoma brain metastasesPD-L1 expressionLower microvessel densityMicrovessel densityBrain metastasesExtracranial metastasesMacrophage contentB cellsProspective therapeutic clinical trialsTumor-infiltrating T cellsImmune-modulating drugsImmune cell subsetsTherapeutic clinical trialsExtracerebral metastasesHigh CD68Low CD3Low CD8Systemic therapyIntracerebral metastasesMetastatic sitesCell subsetsMetastatic melanomaImmune cellsClinical trials
2019
Evolving patterns of metastatic renal cell carcinoma: A meta-analysis.
Lin J, Oh W, Liaw B, Galsky M, Tsao C. Evolving patterns of metastatic renal cell carcinoma: A meta-analysis. Journal Of Clinical Oncology 2019, 37: 563-563. DOI: 10.1200/jco.2019.37.7_suppl.563.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRate of bone metastasesPattern of metastasisBone metastasesClinical trialsRate of lymph node metastasisPattern of metastatic diseaseFirst-line therapyLymph node metastasisRenal cell carcinomaClinical trial patientsTherapeutic clinical trialsRates of lungReport metastasisMetastatic diseaseSecond-lineLiver metastasesCell carcinomaFirst-lineNode metastasisTreatment eraBaseline characteristicsTreatment modalitiesEvaluate temporal trendsTrial patients
2018
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.Peer-Reviewed Original ResearchGermline genetic testingProstate cancerGenetic testingAdvanced diseaseClinical trialsTreatment selectionProstate Cancer Clinical Trials ConsortiumClinical trial eligibility determinationCascade testingClinical Trials ConsortiumTherapeutic clinical trialsGenetic counselingClinical trial purposesTumor genomic profilingPost-test genetic counselingCancer risk assessmentDNA damage repair genesAppropriate genetic counselingTreatment response predictionWorking GroupClinical benefitPrompt testingCancer screeningGenetic testing practicesTreatment decisions
2013
Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.
Pusztai L, Mattair D, Ueno N, Valero V, Moulder S, Murray J, Alvarez R, Chavez-Mac Gregor M, Santiago L, Avritscher R, Sahin A, Hortobagyi G, Symmans W, Meric-Bernstam F, Burton E, Gonzalez-Angulo A. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. Journal Of Clinical Oncology 2013, 31: 532-532. DOI: 10.1200/jco.2013.31.15_suppl.532.Peer-Reviewed Original ResearchFine-needle aspirationCore needle biopsyClinical trial selectionClinical trialsTrial selectionMolecular abnormalitiesTherapeutic clinical trialsSpecific molecular abnormalitiesBreast cancer biopsiesBreast cancer evaluationElectronic medical recordsMutation analysisMechanism of actionCare therapyInvestigational therapiesOrgan dysfunctionPathological confirmationER visitsLymph nodesInvestigational agentsMetastatic sitesMedical recordsEML4-ALKNeedle biopsyNeedle aspirationChapter 80 Autosomal Dominant Polycystic Kidney Disease
Somlo S, Torres V, Caplan M. Chapter 80 Autosomal Dominant Polycystic Kidney Disease. 2013, 2645-2688. DOI: 10.1016/b978-0-12-381462-3.00080-x.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseKidney diseasePolycystic kidney diseaseStructural kidney diseaseMultiple renal cystsAortic root dilatationTherapeutic clinical trialsMitral valve prolapseAbdominal wall herniasLiver bile ductsAge-dependent occurrenceBasic disease mechanismsNoncystic manifestationsRoot dilatationBile ductPolycystic liverSystemic disordersValve prolapseExtrarenal manifestationsClinical trialsPancreatic ductWall herniasRenal cystsClinical disease
2007
Advances in dendritic cell-based therapeutic vaccines for cervical cancer
Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Review Of Anticancer Therapy 2007, 7: 1473-1486. PMID: 17944571, DOI: 10.1586/14737140.7.10.1473.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlphapapillomavirusAnimalsAntigen PresentationAntigens, ViralCancer VaccinesClinical Trials as TopicCombined Modality TherapyDendritic CellsDisease ProgressionDNA-Binding ProteinsFemaleHumansMaleMiceNeoplasmsOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus InfectionsPeptide FragmentsRepressor ProteinsT-Lymphocyte SubsetsUterine Cervical NeoplasmsConceptsCervical cancerDendritic cellsMetastatic diseaseTherapeutic vaccinesDendritic cell-based therapeutic vaccineE7 oncoproteinsPowerful antigen-presenting cellsRecurrent/metastatic diseasePrimary T cell responsesAutologous dendritic cellsInvasive cervical cancerHuman papillomavirus infectionT cell responsesTherapeutic clinical trialsTumor-specific target antigensAntigen-presenting cellsImportant risk factorImportant health problemNovel therapeutic strategiesPapillomavirus infectionRadical surgeryCervical dysplasiaCancer deathRisk factorsClinical trials
1990
Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
Johnson B, Grayson J, Makuch R, Linnoila R, Anderson M, Cohen M, Glatstein E, Minna J, Ihde D. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal Of Clinical Oncology 1990, 8: 396-401. PMID: 2155310, DOI: 10.1200/jco.1990.8.3.396.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerLung cancerLung cancer 2Initiation of chemotherapyTen-year survivalCell lung cancerTherapeutic clinical trialsCranial irradiationCombination chemotherapyOriginal malignancySecond cancersClinical trialsHigh riskPatientsCancer 2CancerChemotherapyMalignancyMore yearsCauseYearsChestDiagnosisTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply